Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells

Conclusions: Lestaurtinib amplifies the ability of the PARP1 inhibitor AG14361 to kill BRCA1 mutant and wild type breast cancer cells, at least in part, by inhibiting NF-kappaB signaling. Each of these drugs has been approved for clinical trials for several different cancers, thus, their combination should be applicable for a breast cancer trial in the future.
Source: Breast Cancer Research - Category: Cancer & Oncology Authors: Source Type: research